Amyloid-based therapies for Alzheimer's disease: From vaccines to secretase inhibitors

William J. Burke, Prasad R. Padala, Daniel L Murman

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Accumulation of β-amyloid protein (Aβ) in the brain is one of the key neuropathologic features of Alzheimer's disease. While current understanding of how Aβ is generated has grown there is still no approved treatment available that either prevents its formation or removes it from the brain. However, numerous treatment strategies are being tested that are aimed at each step of the amyloid pathway - from its initial liberation, to its early aggregation, and finally to the eventual formation of insoluble β-pleated sheets. Today, Aβ is the most accessible therapeutic target available for Alzheimer's disease. In the process of developing treatments based on Aβ modification, there is a great deal to learn not only about Alzheimer's disease but also about the normal function of the brain. This article discusses the current status of various strategies aimed at reducing amyloid burden in the brain.

Original languageEnglish (US)
Pages (from-to)48-52
Number of pages5
JournalPrimary Psychiatry
Volume16
Issue number6
StatePublished - Jun 1 2009

Fingerprint

Amyloid Precursor Protein Secretases
Amyloid
Alzheimer Disease
Vaccines
Brain
Serum Amyloid A Protein
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Amyloid-based therapies for Alzheimer's disease : From vaccines to secretase inhibitors. / Burke, William J.; Padala, Prasad R.; Murman, Daniel L.

In: Primary Psychiatry, Vol. 16, No. 6, 01.06.2009, p. 48-52.

Research output: Contribution to journalReview article

@article{83b3c5fb83a14d14bd4d79618703fa06,
title = "Amyloid-based therapies for Alzheimer's disease: From vaccines to secretase inhibitors",
abstract = "Accumulation of β-amyloid protein (Aβ) in the brain is one of the key neuropathologic features of Alzheimer's disease. While current understanding of how Aβ is generated has grown there is still no approved treatment available that either prevents its formation or removes it from the brain. However, numerous treatment strategies are being tested that are aimed at each step of the amyloid pathway - from its initial liberation, to its early aggregation, and finally to the eventual formation of insoluble β-pleated sheets. Today, Aβ is the most accessible therapeutic target available for Alzheimer's disease. In the process of developing treatments based on Aβ modification, there is a great deal to learn not only about Alzheimer's disease but also about the normal function of the brain. This article discusses the current status of various strategies aimed at reducing amyloid burden in the brain.",
author = "Burke, {William J.} and Padala, {Prasad R.} and Murman, {Daniel L}",
year = "2009",
month = "6",
day = "1",
language = "English (US)",
volume = "16",
pages = "48--52",
journal = "Primary Psychiatry",
issn = "1082-6319",
publisher = "MBL Communications",
number = "6",

}

TY - JOUR

T1 - Amyloid-based therapies for Alzheimer's disease

T2 - From vaccines to secretase inhibitors

AU - Burke, William J.

AU - Padala, Prasad R.

AU - Murman, Daniel L

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Accumulation of β-amyloid protein (Aβ) in the brain is one of the key neuropathologic features of Alzheimer's disease. While current understanding of how Aβ is generated has grown there is still no approved treatment available that either prevents its formation or removes it from the brain. However, numerous treatment strategies are being tested that are aimed at each step of the amyloid pathway - from its initial liberation, to its early aggregation, and finally to the eventual formation of insoluble β-pleated sheets. Today, Aβ is the most accessible therapeutic target available for Alzheimer's disease. In the process of developing treatments based on Aβ modification, there is a great deal to learn not only about Alzheimer's disease but also about the normal function of the brain. This article discusses the current status of various strategies aimed at reducing amyloid burden in the brain.

AB - Accumulation of β-amyloid protein (Aβ) in the brain is one of the key neuropathologic features of Alzheimer's disease. While current understanding of how Aβ is generated has grown there is still no approved treatment available that either prevents its formation or removes it from the brain. However, numerous treatment strategies are being tested that are aimed at each step of the amyloid pathway - from its initial liberation, to its early aggregation, and finally to the eventual formation of insoluble β-pleated sheets. Today, Aβ is the most accessible therapeutic target available for Alzheimer's disease. In the process of developing treatments based on Aβ modification, there is a great deal to learn not only about Alzheimer's disease but also about the normal function of the brain. This article discusses the current status of various strategies aimed at reducing amyloid burden in the brain.

UR - http://www.scopus.com/inward/record.url?scp=75849147610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75849147610&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:75849147610

VL - 16

SP - 48

EP - 52

JO - Primary Psychiatry

JF - Primary Psychiatry

SN - 1082-6319

IS - 6

ER -